271 related articles for article (PubMed ID: 35654820)
21.
Dreisig K; Brünner ED; Marquart HV; Helt LR; Nersting J; Frandsen TL; Jonsson OG; Taskinen M; Vaitkeviciene G; Lund B; Abrahamsson J; Lepik K; Schmiegelow K
Pediatr Hematol Oncol; 2021 Apr; 38(3):227-238. PubMed ID: 33205673
[TBL] [Abstract][Full Text] [Related]
22. [Significance of TPMT activity and TGNs level detection for individualizing 6-mercaptopurine chemotherapy].
Gu LJ; Ye QD; Liang AB; Zhao JC; Xue HL; Tang YN; Chen J; Ye YC
Zhonghua Xue Ye Xue Za Zhi; 2003 Jan; 24(1):18-21. PubMed ID: 12679004
[TBL] [Abstract][Full Text] [Related]
23. Leucocyte versus erythrocyte thioguanine nucleotide concentrations in children taking thiopurines for acute lymphoblastic leukaemia.
Lancaster DL; Patel N; Lennard L; Lilleyman JS
Cancer Chemother Pharmacol; 2002 Jul; 50(1):33-6. PubMed ID: 12111109
[TBL] [Abstract][Full Text] [Related]
24. The Promise of Pharmacogenomics in Reducing Toxicity During Acute Lymphoblastic Leukemia Maintenance Treatment.
Rudin S; Marable M; Huang RS
Genomics Proteomics Bioinformatics; 2017 Apr; 15(2):82-93. PubMed ID: 28391009
[TBL] [Abstract][Full Text] [Related]
25. Novel variant in Nudix hydrolase 15 gene influences 6-mercaptopurine toxicity in childhood acute lymphoblastic leukemia patients.
Sabirova Z; Mahnoor S; Lasfar D; Gagné V; Théorêt Y; Leclerc JM; Laverdière C; Sinnett D; Tran TH; Krajinovic M
Pharmacogenet Genomics; 2024 Jul; 34(5):170-173. PubMed ID: 38682355
[TBL] [Abstract][Full Text] [Related]
26. Pharmacogenetic determinants of mercaptopurine disposition in children with acute lymphoblastic leukemia.
Adam de Beaumais T; Jacqz-Aigrain E
Eur J Clin Pharmacol; 2012 Sep; 68(9):1233-42. PubMed ID: 22421815
[TBL] [Abstract][Full Text] [Related]
27. Individualizing therapy with 6-mercaptopurine and 6-thioguanine related to the thiopurine methyltransferase genetic polymorphism.
Lennard L; Lilleyman JS
Ther Drug Monit; 1996 Aug; 18(4):328-34. PubMed ID: 8857546
[TBL] [Abstract][Full Text] [Related]
28. Differences between children and adults in thiopurine methyltransferase activity and metabolite formation during thiopurine therapy: possible role of concomitant methotrexate.
Pettersson B; Almer S; Albertioni F; Söderhäll S; Peterson C
Ther Drug Monit; 2002 Jun; 24(3):351-8. PubMed ID: 12021625
[TBL] [Abstract][Full Text] [Related]
29. Mercaptopurine induced myelosuppression in a child with a
Gupta N; Magatha LS; Jayaraman D; Scott JX; Antony SB; Koshy T
J Oncol Pharm Pract; 2023 Jun; 29(4):999-1001. PubMed ID: 36341754
[TBL] [Abstract][Full Text] [Related]
30. Methotrexate binds to recombinant thiopurine S-methyltransferase and inhibits enzyme activity after high-dose infusions in childhood leukaemia.
Wennerstrand P; Mårtensson LG; Söderhäll S; Zimdahl A; Appell ML
Eur J Clin Pharmacol; 2013 Sep; 69(9):1641-9. PubMed ID: 23660772
[TBL] [Abstract][Full Text] [Related]
31. Possible implication of thiopurine S-methyltransferase in occurrence of infectious episodes during maintenance therapy for childhood lymphoblastic leukemia with mercaptopurine.
Dervieux T; Médard Y; Verpillat P; Guigonis V; Duval M; Lescoeur B; Suciu S; Vilmer E; Jacqz-Aigrain E
Leukemia; 2001 Nov; 15(11):1706-12. PubMed ID: 11681411
[TBL] [Abstract][Full Text] [Related]
32. Continuing therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of methotrexate, 6-mercaptopurine and 6-thioguanine.
Estlin EJ
Cancer Treat Rev; 2001 Dec; 27(6):351-63. PubMed ID: 11908928
[TBL] [Abstract][Full Text] [Related]
33. Thioguanine offers no advantage over mercaptopurine in maintenance treatment of childhood ALL: results of the randomized trial COALL-92.
Harms DO; Göbel U; Spaar HJ; Graubner UB; Jorch N; Gutjahr P; Janka-Schaub GE;
Blood; 2003 Oct; 102(8):2736-40. PubMed ID: 12843002
[TBL] [Abstract][Full Text] [Related]
34. DNA-thioguanine nucleotide concentration and relapse-free survival during maintenance therapy of childhood acute lymphoblastic leukaemia (NOPHO ALL2008): a prospective substudy of a phase 3 trial.
Nielsen SN; Grell K; Nersting J; Abrahamsson J; Lund B; Kanerva J; Jónsson ÓG; Vaitkeviciene G; Pruunsild K; Hjalgrim LL; Schmiegelow K
Lancet Oncol; 2017 Apr; 18(4):515-524. PubMed ID: 28258828
[TBL] [Abstract][Full Text] [Related]
35. Methylation of mercaptopurine, thioguanine, and their nucleotide metabolites by heterologously expressed human thiopurine S-methyltransferase.
Krynetski EY; Krynetskaia NF; Yanishevski Y; Evans WE
Mol Pharmacol; 1995 Jun; 47(6):1141-7. PubMed ID: 7603453
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics, dose adjustments, and 6-mercaptopurine/methotrexate drug interactions in two patients with thiopurine methyltransferase deficiency.
Andersen JB; Szumlanski C; Weinshilboum RM; Schmiegelow K
Acta Paediatr; 1998 Jan; 87(1):108-11. PubMed ID: 9510461
[TBL] [Abstract][Full Text] [Related]
37. Oral 6-mercaptopurine versus oral 6-thioguanine and veno-occlusive disease in children with standard-risk acute lymphoblastic leukemia: report of the Children's Oncology Group CCG-1952 clinical trial.
Stork LC; Matloub Y; Broxson E; La M; Yanofsky R; Sather H; Hutchinson R; Heerema NA; Sorrell AD; Masterson M; Bleyer A; Gaynon PS
Blood; 2010 Apr; 115(14):2740-8. PubMed ID: 20124218
[TBL] [Abstract][Full Text] [Related]
38. Mercaptopurine/Methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: clinical facts and fiction.
Schmiegelow K; Nielsen SN; Frandsen TL; Nersting J
J Pediatr Hematol Oncol; 2014 Oct; 36(7):503-17. PubMed ID: 24936744
[TBL] [Abstract][Full Text] [Related]
39. De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo.
Dervieux T; Brenner TL; Hon YY; Zhou Y; Hancock ML; Sandlund JT; Rivera GK; Ribeiro RC; Boyett JM; Pui CH; Relling MV; Evans WE
Blood; 2002 Aug; 100(4):1240-7. PubMed ID: 12149204
[TBL] [Abstract][Full Text] [Related]
40. Possible carcinogenic effect of 6-mercaptopurine on bone marrow stem cells: relation to thiopurine metabolism.
Bo J; Schrøder H; Kristinsson J; Madsen B; Szumlanski C; Weinshilboum R; Andersen JB; Schmiegelow K
Cancer; 1999 Sep; 86(6):1080-6. PubMed ID: 10491537
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]